Navigation Links
Cord Blood America Says Debt Reduced $4.194 Million in 2009

SANTA MONICA, Calif., May 27 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company ( ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that it has reduced its secured debt by a total of $4.194 million in the first five months of 2009.

"On April 6th, 2009, Cord Blood America announced it had decreased its debt by $1.75 million this year," said Matthew Schissler, Cord Blood America Founder and CEO. "Since that time, we have further reduced our secured debt by $1.627 million and have eliminated liquidated damages totaling $817,000."

"We have been very forthright with our investors. We have said there are three strong pillars needed to take CBAI to the next level. One is debt reduction, and today's announcement shows our achievement in that sector. The second is organic growth, and our deferred revenues for the first quarter were up 20 percent. The third pillar is acquisitions, and we recently announced Cord Blood America is in the process of building or buying a stem cell laboratory for increased acquisition capacity and higher gross margin," Mr. Schissler said.

"Our strategy for 2009 is in place and we stand by our ability to perform and to make all three pillars strong and sturdy. We urge our shareholders to follow our progress in these important sectors," Cord Blood America's founder said.

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at For investor information, visit

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

        Paul Knopick
        E & E Communications

SOURCE Cord Blood America, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
2. Cord Blood America to Hold Conference Call on Thursday May 21st at 11 a.m. Eastern Time to Discuss 2009 First Quarter Results and Corporate Developments
3. SHARE Program Launched to Address the Challenges of Achieving Blood Pressure Goal
4. Cord Blood America to Acquire or Build Its Own Stem Cell Laboratory
5. Cord Blood America Supports Effort in Congress to Inform on Value of Umbilical Cord Blood Stem Cell Storage
6. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
7. Cord Blood America Further Reduction, $817,000, in Long-Term Debt
8. Cord Blood America Announces 2008 Financial Results
9. Metametrix Introduces the New TRIAD(SM) Bloodspot Profile
10. China Biologic Products Completes Acquisition of 35% Interest in Xian Huitian Blood Products Co., Ltd.
11. Prometheus Receives New York State Approval for PROMETHEUS(R) IBS Diagnostic, First Blood Test for Irritable Bowel Syndrome
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf Association (USGA) today announced ... Section Award. Presented annually since 1961, the USGA Green Section Award recognizes an individual’s ... , Clarke, of Iselin, N.J., is an extension specialist of turfgrass pathology ...
(Date:11/24/2015)... Mass. (PRWEB) , ... November 24, 2015 , ... ... to maintain healthy metabolism. But unless it is bound to proteins, copper is ... of Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic ...
(Date:11/24/2015)... , November 24, 2015 ... market research report "Oligonucleotide Synthesis Market by Product & ... Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & ... by MarketsandMarkets, the market is expected to reach USD ... 2015, at a CAGR of 10.1% during the forecast ...
(Date:11/24/2015)... --> --> ... by Transparency Market Research, the global non-invasive prenatal testing ... 17.5% during the period between 2014 and 2022. The ... Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 ... to reach a valuation of US$2.38 bn by 2022. ...
Breaking Biology Technology:
(Date:11/17/2015)... EASTON, Mass. , Nov. 17, 2015 ... a leader in the development and sale of broadly ... the worldwide life sciences industry, today announced it has ... of its $5 million Private Placement (the "Offering"), increasing ... to $4,025,000.  One or more additional closings are expected ...
(Date:11/12/2015)... 2015  Arxspan has entered into an agreement ... for use of its ArxLab cloud-based suite of ... partnership will support the institute,s efforts to electronically ... information internally and with external collaborators. The ArxLab ... the Institute,s electronic laboratory notebook, compound and assay ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
Breaking Biology News(10 mins):